Form 4: United Therapeutics CFO James Edgemond Executes Stock Options and Sells Shares Under 10b5-1 Plan

James Edgemond, CFO and Treasurer of United Therapeutics, exercised stock options and sold shares of common stock on August 26, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On August 26, 2024, James Edgemond, the CFO and Treasurer of United Therapeutics Corp, executed stock options and sold shares of common stock.
• These transactions were conducted under a pre-arranged Rule 10b5-1 trading plan established on May 17, 2024.
• Edgemond exercised options to acquire 3,266 shares at $120.26 and sold 3,266 shares at $347.6.
• He also exercised options to acquire 3,400 shares at $117.76 and sold 3,400 shares at $347.6.
• Additionally, Edgemond exercised 816 options at $120.26 in a 'sell-to-cover' transaction, selling 557 shares at $347.6 and holding the remaining 259 shares.
• Similarly, he exercised 850 options at $117.76 in a 'sell-to-cover' transaction, selling 576 shares at $347.6 and holding the remaining 274 shares.
• Following these transactions, Edgemond directly owns 2,615 shares of common stock.
• He also holds derivative securities in the form of stock options for 154,000 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The document simply reports stock transactions by an executive under a pre-existing plan. There's no inherent positive or negative implication.

Positives

• The use of a pre-arranged Rule 10b5-1 trading plan suggests that these transactions were planned and not based on insider information.

Industry Context

Executive stock transactions are common and are often scrutinized by investors to gauge management's confidence in the company's future prospects. The use of a 10b5-1 plan provides a structured and transparent framework for these transactions.

Comparison to Industry Standards

• Executive compensation packages often include stock options to align management's interests with those of shareholders.
• Rule 10b5-1 trading plans are a standard practice among corporate executives to avoid accusations of insider trading.
• The size and frequency of these transactions are typical for executives at publicly traded companies.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in the number of outstanding shares.
• The use of a 10b5-1 plan ensures transparency and reduces the risk of insider trading concerns.

Key Dates